Radionuclide development at BNL for nuclear medicine therapy

Mausner, L.F.; Kolsky, K. L.; Joshi, Vishwas N.; Srivastava, Suresh C.

doi:10.1016/s0969-8043(97)00040-7

Cited by 119 publications

(50 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a significant drawback of this production route is the high price of enriched 46 Ca as a result of its extremely low abundance of only 0.004% in natural calcium. Alternative routes for the production of 47 Sc have been reported in the literature (23)(24)(25)(26). Among these, the most feasible appears to be the irradiation of 47 Ti targets with fast neutrons to induce the 47 Ti(n,p) 47 Sc nuclear reaction (25,27,28).…”

Section: Discussionmentioning

confidence: 99%

“…Alternative routes for the production of 47 Sc have been reported in the literature (23)(24)(25)(26). Among these, the most feasible appears to be the irradiation of 47 Ti targets with fast neutrons to induce the 47 Ti(n,p) 47 Sc nuclear reaction (25,27,28). In this respect, more investigations will be necessary to evaluate the production at a larger scale and optimize the isolation conditions of 47 Sc.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice

et al. 2014

View full text Add to dashboard Cite

In recent years, 47 Sc has attracted attention because of its favorable decay characteristics (half-life, 3.35 d; average energy, 162 keV; Eγ, 159 keV) for therapeutic application and for SPECT imaging. The aim of the present study was to investigate the suitability of 47 Sc for radionuclide therapy in a preclinical setting. For this purpose a novel DOTA-folate conjugate (cm10) with an albumin-binding entity was used. Methods: 47 Sc was produced via the 46 Ca(n,γ) 47 Ca! b − 47 Sc nuclear reaction at the high-flux reactor at the Institut Laue-Langevin. Separation of the 47 Sc from the target material was performed by a semi-automated process using extraction chromatography and cation exchange chromatography. 47 Sc-labeled cm10 was tested on folate receptor-positive KB tumor cells in vitro. Biodistribution and SPECT imaging experiments were performed in KB tumor-bearing mice. Radionuclide therapy was conducted with two groups of mice, which received either 47 Sc-cm10 (10 MBq) or only saline. Tumor growth and survival time were compared between the two groups of mice. Results: Irradiation of 46 Ca resulted in approximately 1.8 GBq of 47 Ca, which subsequently decayed to 47 Sc. Separation of 47 Sc from 47 Ca was obtained with 80% yield in only 10 min. The 47 Sc was then available in a small volume (∼500 μL) of an ammonium acetate/HCl (pH 4.5) solution suitable for direct radiolabeling. 47 Sc-cm10 was prepared with a radiochemical yield of more than 96% at a specific activity of up to 13 MBq/nmol. In vitro 47 Sccm10 showed folate receptor-specific binding and uptake into KB tumor cells. In vivo SPECT/CT images allowed the visualization of accumulated radioactivity in KB tumors and in the kidneys. The therapy study showed a significantly delayed tumor growth in mice, which received 47 Sc-cm10 (10 MBq, 10 Gy) resulting in a more than 50% increase in survival time, compared with untreated control mice. Conclusion: With this study, we demonstrated the suitability of using 47 Sc for therapeutic purposes. On the basis of our recent results obtained with 44 Sc-folate, the present work confirms the applicability of 44 Sc/ 47 Sc as an excellent matched pair of nuclides for PET imaging and radionuclide therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Moreover, standard-chelating agents should efficiently bind 47 Sc for targeted radionuclide therapy [9]. Several production methods have been developed including neutron capture on titanium and vanadium targets ( 47 Ti(n,p) 47 Sc, nat Ti(n,x) 47 Sc, nat V(n,x) 47 Sc) [10,11], high-energy proton irradiation of Ti [12,13], as well photo-proton production of 47 Sc via the 48 Ti(c,p) 47 Sc reaction [14,15]. 47 Ca/ 47 Sc generators offer another alternative [12].…”

Section: Photonuclear Productionmentioning

confidence: 99%

“…Several production methods have been developed including neutron capture on titanium and vanadium targets ( 47 Ti(n,p) 47 Sc, nat Ti(n,x) 47 Sc, nat V(n,x) 47 Sc) [10,11], high-energy proton irradiation of Ti [12,13], as well photo-proton production of 47 Sc via the 48 Ti(c,p) 47 Sc reaction [14,15]. 47 Ca/ 47 Sc generators offer another alternative [12]. The method, though, suffers from the drawback that 47 Ca currently can only be obtained through neutron capture and therefore to produce 47 Sc requires a highly enriched 46 Ca target.…”

Section: Photonuclear Productionmentioning

confidence: 99%

Accelerator-based photoproduction of promising beta-emitters 67Cu and 47Sc

Starovoitova

Cole

Grimm

2015

J Radioanal Nucl Chem

View full text Add to dashboard Cite

In this paper we discuss our experimental work in photoproducing two medically-useful radioisotopes ( 68 Zn(c,p) 67 Cu and 48 Ca(c,n) 47 Ca ? 47 Sc) using an electron linear accelerator. We further address the issues of production and separation of medical isotopes arising from photoneutron (c,n) and photoproton (c,p) reactions. While (c,n) reactions typically result in greater yields, separating product nuclides from the target is challenging since the chemical properties of both nuclides are identical. Although the yields of (c,p) reactions are typically lower than for (c,n), these proton-rich isotopes have the advantage that target and product nuclides belong to different chemical species allowing for more straightforward chemical separation. We conclude the paper by touching upon the dire necessity of experimentally revisiting a broad swath of photonuclear reactions in the 10-to 50-MeV regime. The very paucity of empirical cross-sectional data makes it altogether impossible to realistically predict accelerator-based photoproduction of many promising radiopharmaceuticals.

show abstract

“…However the short half-life of 68 Ga (68 minutes) limits its use to the labelling of rapidly diffusible small carriers such as peptides. 44 Sc may be used to quantify the kinetics and the dosimetry of antibodies when radioimmunotherapy is performed using the innovative radionuclide 47 Sc [8]. 52 Fe has a half-life of T 1/2 = 8.275 h and has been used in nuclear medicine mainly for imaging in hematology [9].…”

Section: Great Interest At Short Termmentioning

confidence: 99%

ARRONAX, a high intensity cyclotron in Nantes

Haddad

Michel

Guertin

et al. 2007

Nd2007

View full text Add to dashboard Cite

Abstract.A cyclotron named ARRONAX is being built in Nantes (France). It is mainly devoted to radiochemistry and nuclear medicine research and will be operational the last quarter of 2008. This machine will accelerate both protons and α-particles at high energy (up to 70 MeV) and high intensity (2 simultaneous proton beams with intensity up to 350 µA). In nuclear medicine, these characteristics will allow the cyclotron to produce a large variety of radionuclides on a regular schedule and in sufficient amount to perform clinical trials. A priority list of 12 radioisotopes, which contains isotopes for therapeutic use as well as for PET imaging, has been established by an international scientific committee. In radiochemistry, a vertical pulsed α-beam will allow fundamental studies of radiolysis in aqueous media, which is of great interest for radiobiology and for nuclear waste management.

show abstract

Radionuclide development at BNL for nuclear medicine therapy

Cited by 119 publications

References 22 publications

Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice

Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice

Accelerator-based photoproduction of promising beta-emitters 67Cu and 47Sc

ARRONAX, a high intensity cyclotron in Nantes

Contact Info

Product

Resources

About

Radionuclide development at BNL for nuclear medicine therapy

Cited by 119 publications

References 22 publications

Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice

Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice

Accelerator-based photoproduction of promising beta-emitters 67Cu and 47Sc

ARRONAX, a high intensity cyclotron in Nantes

Contact Info

Product

Resources

About

Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice

Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice